Canada’s IIROC Gets Serious About Naked Shorting: What Could It Mean For Cannabis, Psychedelics, Meme Stocks?
Amid ongoing regulatory scrutiny in the U.S.
Awakn’s Second Licensing Partnership Agreement In A Week, This Time In Canada: Ketamine For Pain Comorbidities
Psychedelics therapeutics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed what constitutes its first licensing partnership deal in Canada.
Psychedelic Acquisition: Psycheceutical To Buy Majority Equity Stake In Maryland R&D Company
Publicly traded psychedelics company Psycheceutical Bioscience Inc. (OTC: BWVI) is signing an exclusive purchase option with end-to-end pharma R&D company Vici Health Sciences’ majority equity stake.
Awakn Enters U.S. Addiction Treatment & Relapse Prevention Market With Ketamine Therapy For Alcohol Use Disorder
Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle and Wellness Ltd.
Major Goals For ATAI: $175M Secured In Term Loan Facility, Plus Q2 Earnings Report
Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc.
Psychedelic Biotech Gets U.K. Study Approval In Treatment Of Depression
Short-acting psychedelics company Small Pharma Inc. (OTCQB: DMTTF) has received the approval from the U.K.
MindMed: Financial And Business Results For Q2 2022, Management And Pipeline Changes
MindMed (NASDAQ: MNMD), which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offer
With EFT Defiance Psychedelics Fund Closing, Let’s Take A Look At Market Movement
The fund owning the Defiance Next Gen Altered Experience ETF (NYSEARCA: PSY) and Defiance Next Gen SPAC Derived ETF funds, ETF Series Solutions recently decided to close and liquidate each fund.
What’s Going On With MindMed? Co-Founder Dr. Scott Freeman Lays Out ‘Value Enhancement Plan’
FCM MM Holdings sent a letter to MindMed’s (NASDAQ: MNMD) board of directors calling on them to adopt a new strategic plan to "turn the company around.”